The CHMP has granted a positive opinion to Vabysmo (faricimab) for treating visual impairment caused by macular edema secondary to retinal vein occlusion (RVO), based on P-III (BALATON & COMINO) studies
The P-III studies (BALATON: n=553 & COMINO: n=729) compare Vabysmo vs aflibercept in BRVO & CRVO patients, respectively, administered with 6 monthly injections of either Vabysmo (6mg) or aflibercept (2mg) for the first 20wks, followed by Vabysmo (6mg, Q4M) with a treat-and-extend regimen at wks.24-72
Studies depicted improved early & sustained visions with strong retinal drying and a well-tolerated safety profile aligning with prior trials
Ref: Roche | Image: Roche
Related News:- Genentech Reports Data from P-III (BALATON and COMINO) Trials of Vabysmo (faricimab-svoa) for Macular Edema due to Retinal Vein Occlusion
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
